Expression of granulocyte colony stimulating factor (GCSF) in Hansenula polymorpha
-
Yeganeh Talebkhan
,
Tannaz Samadi
,
Armin Samie
,
Farzaneh Barkhordari
,
Mohammad Azizi
,
Vahid Khalaj
,
Esmat Mirabzadeh
Abstract
Background and Objectives: During past decades Hansenula polymorpha has attracted global attention for the expression of recombinant proteins due to its high growth rate, minimal nutritional porequirements and use of methanol as a low cost inducer.
Materials and Methods: The corresponding nucleotide sequences for the expression of heterologous genes in Hansenula poylmorpha were extracted and assembled in an E. coli vector. The constructed expression cassette included formate dehy- drogenase promoter (pFMD), a secretory signal sequence, a multiple cloning site (MCS) and methanol oxidase (MOX) ter- minator. Zeocin resistance gene fragment and complete cDNA encoding granulocyte colony stimulating factor (GCSF) were cloned downstream of the expression cassette in-frame with signal sequence. Restriction mapping and sequence analysis confirmed the correct cloning procedures. Final vector was transformed into Hansenula and recombinant host was induced for the expression of GCSF protein by adding methanol. SDS-PAGE and immuno-blotting were performed to confirm the identity of r-GCSF.
Results: The expression cassette containing gcsf gene (615bp) and zeocin resistance marker (sh-ble, 1200bp) was prepared and successfully transformed into competent Hansenula polymorpha cells via electroporation. Zeocin resistant colonies were selected and GCSF expression was induced in recombinant Hansenula transformants using 0.5% methanol and an approx- imately 19kDa protein was observed on SDS-PAGE. Western blot analysis using serum isolated from GCSF-treated rabbit confirmed the identity of the protein.
Conclusions: Molecular studies confirmed the designed expression cassette containing gcsf gene along with pFMD and sig- nal sequence. The expressed 19kDa protein also confirmed the ability of designed vector in expressing heterologous genes in Hansenula cells.
Kamionka M. Engineering of therapeutic proteins pro- duction in Escherichia coli. Curr Pharm Biotechnol 2011; 12: 268-274.
Melmer G. (2005). Biopharmaceuticals and the in- dustrial environment. In: Production of recombinant proteins: novel microbial and eukaryotic expression systems. Ed, G Gellissen. Wiley-VCH, Weinheim. pp.361-383.
Sudbery PE. The non-Saccharomyces yeasts. Yeast 1994; 10: 1707-1726.
van der Klei IJ, Yurimoto H, Sakai Y, Veenhuis M. The significance of peroxisomes in methanol metabolism in methylotrophic yeast. Biochim Biophys Acta 2006;1763: 1453-1462.
Ramezani-Rad M, Hollenberg C, Lauber J, Wedler H, Griess E, Wagner C, et al. The Hansenula polymorpha (strain CBS4732) genome sequencing and analysis. FEMS Yeast Res 2003; 4: 207-215.
Seo HS, Park JS, Han KY, Bae KD, Ahn SJ, Kang HA, et al. Analysis and characterization of hepatitis B vac- cine particles synthesized from Hansenula polymor- pha. Vaccine 2008; 26: 4138-4144.
Gietl C, Faber KN, van der Klei IJ, Veenhuis M. Mu- tational analysis of the N-terminal topogenic signal of watermelon glyoxysomal malate dehydrogenase using the heterologous host Hansenula polymorpha. Proc Natl Acad Sci USA 1994; 91: 3151-3155.
Steinborn G, Böer E, Scholz A, Tag K, Kunze G, Gel- lissen G. Application of a wide-range yeast vector (CoMed™) system to recombinant protein production in dimorphic Arxula adeninivorans, methylotrophic Hansenula polymorpha and other yeasts. Microbial Cell Fact 2006; 5: 33.
Drocourt D, Calmels TPG, Reynes JP, Baron M, Tiraby G. Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucleic Acids Res 1990; 18:4009.
Baron M, Reynes JP, Stassi D, Tiraby G. A Selectable bifunctional β-galactosidase: phleomycin resistance fusion protein as a potential marker for eukaryotic cells. Gene 1992; 114: 239-243.
Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Ya- mazaki T. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 1990; 107: 486-492.
vanDijk R, Faber KN, Hammond AT, Glick BS, Veen- huis M, Kiel JAKW. Tagging Hansenula polymorpha genes by random integration of linear DNA fragments (RALF). Mol Genet Genomics 2001; 266: 646-656.
Waterham HR, Digan ME, Koutz PJ, Lair SV, Cregg JM. Isolation of the Pichia pastoris glyceralde- hyde-3-phosphate gene and regulation and use of its promoter. Gene 1997; 186: 37-44.
Yurimoto H, Sakai Y, Kato N (2002) Methanol metab- olism. In: Hansenula polymorpha- Biology and Appli- cations. Ed, G Gellissen. Wiley-VCH, Weinheim, pp.61-75.
Barnes CS, Krafft B, Freeh M, Hofmann UR, Pa- pendieck A, Dahlems U, et al. Production and charac- terization of saratin, an inhibitor of von Willebrand's factor-dependent platelet adhesion to collagen. Semin Thromb Hemost 2001; 27: 337-347.
Kang HA, Gellissen G (2005) Hansenula polymor- pha. In: Production of Recombinant Proteins – Novel Microbial and Eukaryotic Expression Systems. Ed, G Gellissen. Wiley-VCH, Weinheim, pp. 111-142.
Eggeling L, Sahm H. Derepression and partial insen- sitivity to carbon catabolite repression of the methanol dissimilating enzymes in Hansenula polymorpha. Eur J Appl Microbiol Biotechnol 1978; 5:197-202.
Gellissen G, Melber K. Methylotrophic yeast Hansenu- la polymorpha as production organism for recombinant pharmaceuticals. Arzneimittelforschung 1996; 46: 943-948.
Martinez JL, Liu L, Petranovic D, Nielsen J. Pharma- ceutical protein production by yeast: towards produc- tion of human blood proteins by microbial fermenta- tion. Curr Opin Biotechnol 2012; 23: 965-971.
Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov Today 2010; 15: 773-780.
Berlec A, Strukelj B. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. J Ind Microbiol Biotech- nol 2013; 40: 257-274.
Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010; 28: 917-924.
Janowicz ZA, Melber K, Merckelbach A, Jacobs E, Harford N, Comberbach M, et al. Simultaneous ex- pression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha. Yeast 1991; 7: 431-443.
Gellissen G, Strasser AWM, Suckow M (2005). Key and criteria to the selection of an expression platform. In: Production of Recombinant Proteins – Novel Mi- crobial and Eukaryotic Expression Systems. Ed, G Gel- lissen. Wiley-VCH, Weinheim, pp. 1-5.
Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Purification and characterization of hepatitis B vi- rus surface antigen particles produced in Drosophila Schneider-2 cells. J Virol Methods 1999; 79: 205-217.
Hamilton SR, Gerngross TU. Glycosylation engineer- ing in yeast: the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18: 387-392.
Cheon SA, Kim H, Oh DB, Kwon O, Kang HA. Re- modeling of the glycosylation pathway in the meth- ylotrophic yeast Hansenula polymorpha to produce human hybrid-type N-glycans. J Microbiol 2012; 50:341-348.
Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycopro- teins. Biochemistry 1996; 35: 7299-7307.
Arakawa T, Prestrelski S, Narhi L, Boone T, Kenney W.Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Pro- tein Chem 1993; 12: 525-531.
| Files | ||
| Issue | Vol 8 No 1 (2016) | |
| Section | Articles | |
| Keywords | ||
| Hansenula polymorpha expression cassette GCSF | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
